Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration

Ophthalmology

Volumn 119, Issue 11, 2012, Pages 2304-2311

  Smailhodzic, Dzenita ^a   Muether, Philipp S ^b   Chen, John ^c   Kwestro, Angela ^a   Zhang, Alice Yang ^c   Omar, Amer ^c   Van De Ven, Johannes P H ^a   Keunen, Jan E E ^a   Kirchhof, Bernd ^b   Hoyng, Carel B ^a   Klevering, B Jeroen ^a   Koenekoop, Robert K ^c   Fauser, Sascha ^b   Den Hollander, Anneke I ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF COLOGNE   (Germany)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AGE RELATED MACULOPATHY SUSCEPTIBILITY PROTEIN 2; COMPLEMENT FACTOR H; FZD4 PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; PROTEIN; RANIBIZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ADULT; ALLELE; ANGIOGENESIS; ARTICLE; COHORT ANALYSIS; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VISUAL ACUITY;

AGE OF ONSET; AGED; AGED, 80 AND OVER; ALLELES; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; COMPLEMENT FACTOR H; FEMALE; FLUORESCEIN ANGIOGRAPHY; FRIZZLED RECEPTORS; GENOTYPE; HUMANS; INTRAVITREAL INJECTIONS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-5; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEINS; RISK FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84868194934     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2012.05.040     Document Type: Article

References (37)

1. Eye Diseases Prevalence Research Group Prevalence of age-related macular degeneration in the United States Arch Ophthalmol 122 2004 564 572
2. R. Klein, B.E. Klein, S.C. Tomany Ten-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study Ophthalmology 109 2002 1767 1779
3. P. Mitchell, W. Smith, K. Attebo, J.J. Wang Prevalence of age-related maculopathy in Australia: the Blue Mountains Eye Study Ophthalmology 102 1995 1450 1460
4. N. Ferrara, H.P. Gerber, J. LeCouter The biology of VEGF and its receptors Nat Med 9 2003 669 676
5. R.N. Frank, R.H. Amin, D. Eliott Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes Am J Ophthalmol 122 1996 393 403
6. M. Kliffen, H.S. Sharma, C.M. Mooy Increased expression of angiogenic growth factors in age-related maculopathy Br J Ophthalmol 81 1997 154 162
7. P.F. Lopez, B.D. Sippy, H.M. Lambert Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes Invest Ophthalmol Vis Sci 37 1996 855 868
8. P.U. Dugel Ranibizumab treatment of patients with ocular diseases Int Ophthalmol Clin 46 2006 131 140
9. P.J. Rosenfeld, D.M. Brown, J.S. Heier MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
10. M. Menghini, M.M. Kurz-Levin, C. Amstutz Response to ranibizumab therapy in neovascular AMD: an evaluation of good and bad responders Klin Monbl Augenheilkd 227 2010 244 248
11. I.S. Chan, G.S. Ginsburg Personalized medicine: progress and promise Annu Rev Genomics Hum Genet 12 2011 217 244
12. Q. Ma, A.Y. Lu Pharmacogenetics, pharmacogenomics, and individualized medicine Pharmacol Rev 63 2011 437 459
13. A.O. Edwards, R. Ritter III, K.J. Abel Complement factor H polymorphism and age-related macular degeneration Science 308 2005 421 424
14. R.J. Klein, C. Zeiss, E.Y. Chew Complement factor H polymorphism in age-related macular degeneration Science 308 2005 385 389
15. D.E. Weeks, Y.P. Conley, H.J. Tsai Age-related maculopathy: a genomewide scan with continued evidence of susceptibility loci within the 1q31, 10q26, and 17q25 regions Am J Hum Genet 75 2004 174 189
16. B. Kloeckener-Gruissem, D. Barthelmes, S. Labs Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD Invest Ophthalmol Vis Sci 52 2011 4694 4702
17. A.Y. Lee, A.K. Raya, S.M. Kymes Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab 80 Br J Ophthalmol 93 2009 610 613
18. M. McKibbin, M. Ali, S. Bansal CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration Br J Ophthalmol 96 2012 208 212
19. S.J. Teper, A. Nowinska, J. Pilat Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration Mol Vis [serial online] 16 2010 2598 2604 http://www.molvis.org/molvis/v16/a278/ Accessed May 19, 2012
20. L.A. Yannuzzi, S. Negrao, T. Iida Retinal angiomatous proliferation in age-related macular degeneration Retina 21 2001 416 434
21. S. Wolf Current status of anti-vascular endothelial growth factor therapy in Europe Jpn J Ophthalmol 52 2008 433 439
22. CATT Research Group Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 2011 1897 1908
23. I. Immonen, S. Seitsonen, P. Tommila Vascular endothelial growth factor gene variation and the response to photodynamic therapy in age-related macular degeneration Ophthalmology 117 2010 103 108
24. J.M. Seddon, P.J. Francis, S. George Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration JAMA 297 2007 1793 1800
25. H.P. Scholl, P. Charbel Issa, M. Walier Systemic complement activation in age-related macular degeneration PLoS One [serial online] 3 2008 e2593 http://www.molvis.org/molvis/v16/a278/ Accessed May 19, 2012
26. D. Smailhodzic, C.C. Klaver, B.J. Klevering Risk alleles in CFH and ARMS2 are independently associated with systemic complement activation in age-related macular degeneration Ophthalmology 119 2012 339 346
27. M. Nozaki, B.J. Raisler, E. Sakurai Drusen complement components C3a and C5a promote choroidal neovascularization Proc Natl Acad Sci U S A 103 2006 2328 2333
28. B. Rohrer, Q. Long, B. Coughlin A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration Invest Ophthalmol Vis Sci 50 2009 3056 3064
29. M. Shahbazi, A.A. Fryer, V. Pravica Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection J Am Soc Nephrol 13 2002 260 264
30. N. Leveziel, J. Zerbib, F. Richard Genotype-phenotype correlations for exudative age-related macular degeneration associated with homozygous HTRA1 and CFH genotypes Invest Ophthalmol Vis Sci 49 2008 3090 3094
31. P.J. Rosenfeld, H. Shapiro, L. Tuomi MARINA Study Group ANCHOR Study Group Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials Ophthalmology 118 2011 523 530
32. M.T. Andreoli, M.A. Morrison, B.J. Kim Comprehensive analysis of complement factor H and LOC387715/ARMS2/HTRA1 variants with respect to phenotype in advanced age-related macular degeneration Am J Ophthalmol 148 2009 869 874
33. H. Bessho, S. Honda, N. Kondo, A. Negi The association of age-related maculopathy susceptibility 2 polymorphisms with phenotype in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy Mol Vis [serial online] 17 2011 977 982 http://www.molvis.org/molvis/v17/a108/ Accessed May 19, 2012
34. M.A. Brantley Jr, A.M. Fang, J.M. King Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab Ophthalmology 114 2007 2168 2173
35. S. Seitsonen, I. Jarvela, S. Meri Complement factor H Y402H polymorphism and characteristics of exudative age-related macular degeneration lesions Acta Ophthalmol 86 2008 390 394
36. Age-Related Eye Disease Study Research Group A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8 Arch Ophthalmol 119 2001 1417 1436
37. P. Charbel Issa, N.V. Chong, H.P. Scholl The significance of the complement system for the pathogenesis of age-related macular degeneration - current evidence and translation into clinical application Graefes Arch Clin Exp Ophthalmol 249 2011 163 174